Circulating Tumor DNA and Management of Colorectal Cancer
Although the incidence of colorectal cancer (CRC) has decreased as a result of increased screening and awareness, it still remains a major cause of cancer-related death. Additionally, early detection of CRC recurrence by conventional means such as CT, endoscopy, and CEA has not translated into an im...
Main Authors: | Matthew Krell, Brent Llera, Zachary J. Brown |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/16/1/21 |
Similar Items
-
Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis
by: Estela Sánchez-Herrero, et al.
Published: (2022-07-01) -
Hypermethylated GRIA4, a potential biomarker for an early non-invasive detection of metastasis of clinically known colorectal cancer
by: Eva Lukacova, et al.
Published: (2023-07-01) -
Editorial: Recent advances in liquid biopsy in colorectal cancer
by: Claudia Cardone, et al.
Published: (2022-12-01) -
The Role of Biomarkers in the Management of Colorectal Liver Metastases
by: Daniel Brock Hewitt, et al.
Published: (2022-09-01) -
Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care
by: Maren Hedtke, et al.
Published: (2022-05-01)